Standaert, Baudouin http://orcid.org/0000-0001-6801-9654
Sauboin, Christophe http://orcid.org/0000-0003-0913-039X
Leclerc, Quentin J. http://orcid.org/0000-0003-4761-001X
Connolly, Mark P. http://orcid.org/0000-0002-1886-745X
Funding for this research was provided by:
UK Medical Research Council (MR/N013638/1)
GlaxoSmithKline Biologicals S.A.
Article History
Accepted: 31 October 2020
First Online: 25 November 2020
Declarations
:
: GlaxoSmithKline Biologicals S.A. funded this study (GSK study identifier: HO-18-19703) and all costs related to the development and publication of this manuscript. Q. Leclerc reports a grant from UK Medical Research Council during the conduct of the study (grant no. MR/N013638/1).
: B Standaert was an employee of the GSK group of companies during the study conduct and holds stock in the GSK group of companies. C. Sauboin was an employee of the GSK group of companies during the study conduct. M. Connolly declares he has consulted for the GSK group of companies in the past and received no financial compensation for the development of this manuscript. Q. Leclerc has no financial conflicts of interests to disclose. Authors declare no other financial and non-financial relationships and activities.
: Data and material may be found in Kotsopoulos et al., 2019 [CitationRef removed].
: MS Excel and @Risk Palisade, 8.0.
: All authors participated in the design or implementation or analysis and interpretation of the study; all authors participated in the development of this manuscript. All authors had full access to the data and gave final approval before submission.
: <i>Rotarix</i> is a trademark owned by or licensed to the GSK group of companies. <i>Rotateq</i> is a trademark owned by or licensed to Merck & Co, USA.